Hydrocortisone Suspension Provides Similar Growth Outcomes as Hydrocortisone Tablets in Young Children with Congenital Adrenal Hyperplasia: A Cross Sectional Study.
2021-08
Loading...
View/Download File
Persistent link to this item
Statistics
View StatisticsJournal Title
Journal ISSN
Volume Title
Title
Hydrocortisone Suspension Provides Similar Growth Outcomes as Hydrocortisone Tablets in Young Children with Congenital Adrenal Hyperplasia: A Cross Sectional Study.
Authors
Published Date
2021-08
Publisher
Type
Thesis or Dissertation
Abstract
BACKGROUND. Young children with CAH require small doses (0.1-1.25 mg) of hydrocortisone (HC) to control excess androgen production and to avoid the negative effects of overtreatment. The smallest commercially available HC formulation, before the recent FDA approval of HC granules, was a scored 5 mg tablet. The options to achieve small doses were limited to using a pharmacy-compounded suspension, which the CAH Clinical PracticeGuidelines recommends against, or splitting tablets into quarters or eighths, or dissolving tablets
into water.
METHODS. Cross sectional chart review of 130 children with classic CAH treated with tablets versus a pharmacy-compounded alcohol-free hydrocortisone suspension to compare growth, weight, skeletal maturation, total daily HC dose, and total HC exposure over the first four years of life.
RESULTS. No significant differences were found in height, weight, or BMI z-scores at 4 years, and in predicted adult height, before or after adjusting for age at diagnosis and sex. Bone age z- scores averaged 2.78 SDs lower for patients treated with HC suspension compared to HC tablets after adjusting for sex and age at diagnosis (p<0.001). The suspension group received 30.4% lower (p<0.001) average cumulative HC doses by their 4th birthday.
CONCLUSIONS. Our data indicates that treatment with alcohol-free HC suspension decreased androgen exposure as shown by lower bone age z-scores, allowed lower average and cumulative daily HC dose compared to HC tablets, and generated no significant differences in SDS in growth parameters in children with CAH at 4 years of age. Long-term outcomes of treating children with CAH with smaller HC doses during childhood need to be studied.
Description
University of Minnesota M.S. thesis. August 2021. Major: Clinical Research. Advisor: Kyriakie Sarafoglou. 1 computer file (PDF); iv, 28 pages.
Related to
Replaces
License
Series/Report Number
Funding information
Isbn identifier
Doi identifier
Previously Published Citation
Suggested citation
Al-Rayess, Heba. (2021). Hydrocortisone Suspension Provides Similar Growth Outcomes as Hydrocortisone Tablets in Young Children with Congenital Adrenal Hyperplasia: A Cross Sectional Study.. Retrieved from the University Digital Conservancy, https://hdl.handle.net/11299/259535.
Content distributed via the University Digital Conservancy may be subject to additional license and use restrictions applied by the depositor. By using these files, users agree to the Terms of Use. Materials in the UDC may contain content that is disturbing and/or harmful. For more information, please see our statement on harmful content in digital repositories.